Santen Pharmaceutical Co., Ltd.

Ayumi Pharmaceutical Corporation

Atsuyoshi Dota

Masatsugu Nakamura

Toshiyuki Mori

Masatomo Kato

Mamoru Matsuda

Miwa Takai

Takashi Nagano

Takahiro Matsuyama

Tatsuji Kurose

Yumi Hagiwara

Asuka Sakamoto

Yuko Shichijo

Kenji Imoto

Nagano Takashi

Nakamura Masatsugu

Sakamoto Asuka

An agent for treatment of dry eye comprising a combination of a P2Yreceptor agonist at a therapeutically effective concentration and hyaluronic acid or a salt thereof at a therapeutically effective concentration, which agent has a dosage form of an ophthalmic agent, can promote the secretion of tear remarkably and can improve corneal epithelial disorders remarkably, and is therefore expected to be a novel agent for treatment of dry eye.

[object Object]

The present invention is related to glucocorticoid receptor agonists comprised of a compound represented by formula (1) which is 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivative or a salt thereof and novel pharmacological effects of the glucocorticoid receptor agonists. In the formula (1), Rrepresents formula (2a), (3a), (4a) or (5a); R2 represents &#x2014;(CO)&#x2014;R8, &#x2014;(CO)O&#x2014;R9, or the like; R&#x2014;O&#x2014; is substituted at the 4- or -5-position of benzene ring A; Rrepresents a lower alkyl group; R, R, Ror Rrepresents a halogen atom, a lower alkyl group which may have a substituent, or the like; m, n, p or q represents 0, 1 or the like; R, Ror the like represents a lower alkyl group which may have a substituent, a lower alkenyl group, or the like. 

Glucocorticoid receptor agonist comprising 2,2,4-trimethyl-6-phenyl-1,2-dihydroquinoline derivatives having substituted oxy group

Growing community of inventors

Nara, Japan

Atsuyoshi Dota